|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT01191710 |
|
Date of registration:
|
27/08/2010 |
|
Primary sponsor: |
|
|
Public title:
|
Progesterone Rise in Agonist Versus Antagonist in Vitro Fertilization (IVF) Cycles
|
|
Scientific title:
|
Is the Clinical Outcome Affected by the Incidence of Progesterone Elevation on the Day of hCG Triggering When Agonist Protocol is Compared to Antagonist Protocol for IVF |
|
Date of first enrolment:
|
January 2007 |
|
Target sample size:
|
200 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT01191710 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
Greece
| | | | | | | |
|
Contacts
|
|
Name:
|
Basil Tarlatzis, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
BioGenesis |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- age < 39
- follicle-stimulating hormone (FSH) < 12
- gonadotropin dose 100-300IU
Exclusion Criteria:
- endometriosis
- known endocrine disorder
- blood analyzed in another laboratory
Age minimum:
21 Years
Age maximum:
39 Years
Gender:
Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Pregnancy Outcome After In Vitro Fertilization (IVF)
|
|
Intervention(s)
|
|
Other: In vitro fertilization
|
|
Primary Outcome(s)
|
|
Incidence of late progesterone rise on the day of HCG triggering
[Time Frame: Up to delivery (2010)]
|
|
Secondary Outcome(s)
|
|
Clinical pregnancy rate Delivery rate
[Time Frame: Up to delivery (2010)]
|
|
Secondary ID(s)
|
|
ProgRise001
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|